SYX-5219 Oral Capsule Clinical Trials (2026): 1 Studies for Moderate to Severe Atopic Dermatitis

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: .

1 SYX-5219 Oral Capsule clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Moderate to Severe Atopic Dermatitis) and 149 total planned enrollment. 1 SYX-5219 Oral Capsule clinical trial is actively recruiting at 6 U.S. sites across 6 states. Most recent activity: NCT07558668 (Sep 2026).

Where to Participate: All SYX-5219 Oral Capsule Trial Sites in the U.S. (6 sites across 6 states)

Every actively recruiting SYX-5219 Oral Capsuletrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

StateFacilityCityTrialMap
ARSitryx Clinical SiteArkansas City72117NCT07558668Map
CASitryx Clinical SiteFremont94538NCT07558668Map
INSitryx Clinical SitePlainfield46168NCT07558668Map
OHSitryx Clinical SiteBoardman44512NCT07558668Map
PASitryx Clinical SitePhiladelphia19103NCT07558668Map
UTSitryx Clinical SiteBountiful84010NCT07558668Map

SYX-5219 Oral Capsule clinical trials at a glance: phase × recruitment status

PhaserecruitingTotal
P111

Recruiting SYX-5219 Oral Capsule clinical trials (1)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT IDTitlePhaseIndicationEnrollmentStarted
NCT07558668A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic DermatitisP1Moderate to Severe Atopic Dermatitis149Feb 2025

All SYX-5219 Oral Capsule trials (1)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT IDAcronymTitlePhaseStatusEnrollmentSponsorStarted
NCT07558668A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic DermatitisP1recruiting149Sitryx Therapeutics LtdFeb 2025

SYX-5219 Oral Capsule clinical trials: frequently asked questions

How many SYX-5219 Oral Capsule clinical trials are there?
1 SYX-5219 Oral Capsule clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
Are SYX-5219 Oral Capsule clinical trials recruiting in 2026?
Yes — 1 SYX-5219 Oral Capsule trial is actively recruiting in 2026, with 6 U.S. sites across 6 states. See the recruiting trials and the per-state site list further down this page.
What conditions is SYX-5219 Oral Capsule being studied for?
SYX-5219 Oral Capsule is being studied for Moderate to Severe Atopic Dermatitis. The trials are grouped by indication on this page.
What phase is SYX-5219 Oral Capsule in?
SYX-5219 Oral Capsule clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors SYX-5219 Oral Capsule clinical trials?
The lead sponsor across the most SYX-5219 Oral Capsule trials is Sitryx Therapeutics Ltd. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming SYX-5219 Oral Capsuleas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed .

Related pages on Hipa.ai:

SYX-5219 Oral Capsule Clinical Trials (2026): 1 Studies | Hipa.ai